NCT03179397 is a NA clinical trial of Model SC9 in Cataract, sponsored by CORD, LLC.

Who is sponsoring NCT03179397?

NCT03179397 is sponsored by CORD, LLC.

What drugs are being tested in NCT03179397?

Interventions in NCT03179397: Model SC9, Model LI61SE.

Is NCT03179397 still recruiting?

NCT03179397 is currently terminated. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT03179397

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Model SC9 IOL Compared to the Model LI61SE IOL (Bausch & Lomb)

Terminated NA Last updated 30 August 2023

What this trial tests

NA trial testing Model SC9 in Cataract in 338 participants. Terminated before completion.

Timeline

31 May 2017

Primary endpoint
4 October 2021

22 July 2023

Quick facts

Lead sponsor	CORD, LLC
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	338
Start date	31 May 2017
Primary completion	4 October 2021
Estimated completion	22 July 2023
Sites	13 locations across United States

Drugs / interventions tested

Model SC9
Model LI61SE

Conditions studied

Cataract — all drugs for Cataract →

Sponsor

CORD, LLC

Who can join

22 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the Model SC9 Intraocular Lens for the improvement of near and intermediate vision when compared to a legally marketed monofocal IOL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03179397 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CORD, LLC
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03179397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing